Digital Angel Corporation, a provider of implantable medical device identification and radiation dose measurement technologies following its recent share exchange with VeriTeQ Acquisition Corporation, announced today that it has received its first order for its Q Inside implantable microchip for unique device identification from Establishment Labs, S.A., the Company’s partner in the breast implant market, for September delivery. EL has received its first order from a customer in the European Union to offer the world’s first traceable breast implant with “Q Inside” to patients. EL has filed for CE mark for its Motiva Implant Matrix® implants with “Q Inside” to be marketed in Europe.
VeriTeQ’s “Q Inside,” a passive radio frequency identification (“RFID”) microchip, enables implantable medical devices to be quickly and safely identified from outside the body. Motiva Breast Implants® with “Q Inside” are designed to enable a manufacturer, physician or patient to access a secure online database and retrieve implant-specific data such as serial number, manufacturer name, date of manufacture, lot number, volume, size, and other data. In September 2012, VeriTeQ entered into a development and supply agreement with EL, a global provider of breast implants under the Motiva Implant Matrix® brand name, to build next-generation breast implants that contain VeriTeQ’s Unique Device Identifier (“UDI”) called “Q Inside.” “We believe EL’s agreement with a leading operator of plastic surgery centers in the EU to offer Motiva breast implants with ‘Q Inside’ provides significant validation for our technology and the market need to identify implantable medical devices from within the body,” stated Scott R. Silverman, Chairman and Chief Executive Officer of VeriTeQ.